1146 Evidence-Based Medicine [ 1 5 4 # 5 C H E S T N O V E M B E R 2 0 1 8 ] TABLE 3 ] Risk Factors, Risk Categories and Bleeding Events in the Validation Cohorts Risk Score Risk Factors (Score for Each Factor) Risk Categories Bleeding Events in Validation Cohort (per 100 patient-years) Low Intermediate High Low Intermediate High Agea ; biomarkersa (GDF-15 or cystatin C/CKD-EPI, cTnT-hs, and Hb); previous bleeda history (2); Y renal function (1); APT (1) Anemia (3); severe renal disease (3); age $ 75 [SBP (1); severe renal/hepatic disease (1 each); stroke (1); bleeding (1); labile INR (1); age > Hepatic/renal disease (1); ethanol abuse (1); malignancy; age > 75 y (1); YPlt (1); re-bleeding risk (2); [BP (1); anemia (1); genetic factors Shireman et al102 Age $ 70 y (0.49); female (0.31); previous bleed (0.58); recent bleed (0.62); alcohol/drug abuse Y reduced/decreased; [ elevated/increased; ABC Atrial brillation Better Care; APT antiplatelet therapy; ATRIA Anticoagulation and Risk Factors in Atrial Fibrillation; CKD-EPI Chronic Kidney Disease Epidemiology Collaboration; cTnT-hs high-sensitivity troponin T; DM diabetes mellitus; GDF-15 growth differentiation factor-15; HAS-BLED hypertension, abnormal renal/liver function (1 point each), stroke, bleeding history or predisposition, labile INR, elderly (.65), drugs/alcohol concomitantly (1 point each); Hb hemoglobin; Hct hematocrit; HEMORR2HAGES hepatic or renal disease, ethanol abuse, malignancy, older, reduced platelet count/function, hypertension, anemia, genetic factors, excessive fall risk, and stroke; INR international normalized ratio; NSAIDs nonsteroidal antiin ammatory drugs; ORBIT Outcomes Registry for Better Informed Treatment of Atrial Fibrillation Registry; Plt platelet count or function; SBP systolic BP. See Table 1 legend for expansion of other abbreviation. (Partly reproduced with permission from Zulki y et al.103 ) a Score for each variable in ABC score is based on a nonogram (see reference100 ). 